Get started
Author

Dylan Therwhanger

ORCID: 0009-0003-9423-1941
Observed ORCID: 0009-0003-9423-1941
OpenAlex ID: A5093399642
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma
2024 · Elise A. Chong, Emeline R. Chong, et al. · Transplantation and Cellular Therapy · 11
Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
2025 · Zachary D. Epstein-Peterson, Anath C. Lionel, et al. · Blood Advances · 7
PDF
Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma
2024 · Gloria Iacoboni, Emil Ramsø Kyvsgaard, et al. · Blood · 6
Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma
2026 · Gloria Iacoboni, Emil Ramsø Kyvsgaard, et al. · Blood Advances · 5
PDF
Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
2024 · Zachary D. Epstein-Peterson, Anath C. Lionel, et al. · Blood · 3
Safety of CAR-T Cell Therapy in Asymptomatic Patients with Positive Respiratory Viral Testing Prior to CAR-T Infusions
2023 · Reid M. Muenzen, Emeline R. Chong, et al. · Blood · 1
PDF
Resolution of Ibrutinib-Associated Hypertension with Transition to Alternate Covalent Bruton's Tyrosine Kinase Inhibitor
2024 · Emily B. Tomasulo, Dylan Therwhanger, et al. · Blood
PDF
Works count: 7
Citation count: 33
H-index: 4
I10-index: 1
Year
Topic
Type